𝔖 Bobbio Scriptorium

✦ LIBER ✦

Robust methods to improve efficiency and reduce bias in estimating survival curves in randomized clinical trials

✍ Scribed by Zhang, Min

Book ID: 121553393
Publisher: Springer
Year: 2014
Tongue: English
Weight: 252 KB
Volume: 21
Category: Article
ISSN: 1380-7870
DOI: 10.1007/s10985-014-9291-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficient and robust method for comparin

Efficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trials

✍ Peter B. Gilbert; Alicia Sato; Xiao Sun; Devan V. Mehrotra 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 368 KB

A Comparison of Methods for Estimating t

A Comparison of Methods for Estimating the Causal Effect of a Treatment in Randomized Clinical Trials Subject to Noncompliance

✍ Roderick J. Little; Qi Long; Xihong Lin 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB

A novel Laser Navigation System reduces

A novel Laser Navigation System reduces radiation exposure and improves accuracy and workflow of CT-guided spinal interventions: A prospective, randomized, controlled, clinical trial in comparison to conventional freehand puncture

✍ Moser, Carsten; Becker, Jan; Deli, Martin; Busch, Martin; Boehme, Marc; Groeneme 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 404 KB

Review finds primary stenting lowers the

Review finds primary stenting lowers the risk of reinfarction and revascularisation, but does not improve survival compared to balloon angioplasty: Abstracted from: Nordmann AJ, Hengstler P, Harr T, et al. Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials. Am J Med. 2004; 116: 253–62.

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 127 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB